Codeine is bioactivated by CYP2D6 into morphine, which then undergoes further glucuronidation. CYP2D6 genotyping showed that the patient had three or more functional alleles, a finding consistent ...

February 9, 2009 — In clinical practice, there is a "hesitation" about testing for CYP2D6 before prescribing tamoxifen to reduce the risk for breast cancer recurrence, observes an editorial ...

A U-shaped association was found between CYP2D6 metabolizer status and breast cancer–specific mortality, with adjusted hazard ratios of 2.59 (95% CI, 1.01 to 6.67) for poor, 1.48 (95% CI, 0.72 to 3.05 ...

Paroxetine is a strong inhibitor of the CYP2D6 enzyme that converts tamoxifen to its active metabolite, reducing the amount of active drug that is released. "We found that women with breast cancer ...

The association between tamoxifen adherence and breast cancer recurrence has never been reported. Furthermore, adherence is possibly related to CYP2D6 inhibitor use. Conceivably, patients who use ...

The researchers found that use of CYP2D6-metabolized opioids concomitantly with CYP2D6-inhibiting antidepressants was associated with increased adjusted rate ratio of worsening pain compared with ...

CYP2D6 genotype is an inherited factor that alters the metabolism of tamoxifen. Tamoxifen is converted through the process of liver metabolism into forms that result in greater anti-estrogenic ...

Credit: Shutterstock. According to HF guidelines, beta-blockers must be titrated to a specific target dose in order to obtain their morbidity and mortality benefit in HF patients. According to a ...

3,8 As dextromethorphan is a substrate for CYP2D6 and quinidine is an inhibitor of CYP2D6 and p-glycoprotein, there is the potential for drug interactions. 44 Dose reductions of desipramine ...

Conversion from other opioids: see full labeling. Concomitant use or discontinuation of CYP2D6 inhibitors, CYP3A4 inhibitors or inducers: monitor closely and consider dose adjustments (see full ...